An AMY1 receptor agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Eloralintide (acetate)

Item No. 45770

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-γ-glutamyl-S-(mercaptomethyl)-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonylglycyl-L-ornithyl-L-leucyl-L-alanyl-L-α-glutamyl-α-methyl-L-phenylalanyl-L-leucyl-L-valyl-L-arginyl-L-seryl-L-seryl-L-asparaginyl-N-methyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-N-[N-(19 carboxy-1-oxononadecyl)-L-γ-glutamyl-L-γ-glutamyl]-L-lysyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-α-glutamyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-L-tyrosinamide, cyclic (2→7)-thioether, acetate
Molecular Formula
C201H319N49O65S2 • XC2H4O2
Formula Weight
4526.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
γE-[CNTATC]ATG-Orn-LAE-α-Me-L-Phe-LVRSSN-N-Me-Asn-FGPK(γE-C20 diacid)-LPPTEVGSNTY-NH2
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/ml
SMILES
OC1=CC=C(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]2N(CCC2)C([C@H]3N(CCC3)C([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C(CNC([C@@H](NC([C@@H](N(C)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@](C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC5=O)CC(N)=O)=O)[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CSCSC[C@@H]5NC(CC[C@H](N)C(O)=O)=O)=O)C)=O)[C@@H](C)O)=O)=O)CCCN)=O)CC(C)C)=O)C)=O)CCC(O)=O)=O)CC6=CC=CC=C6)=O)CC(C)C)=O)C(C)C)=O)CCCNC(N)=N)=O)CO)=O)CO)=O)CC(N)=O)=O)CC(N)=O)=O)CC7=CC=CC=C7)=O)=O)=O)CCCCNC(CC[C@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(O)=O)=O)=O)CC(C)C)=O)=O)=O)[C@@H](C)O)=O)CCC(O)=O)=O)C(C)C)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O)C(N)=O)C=C1.CC(O)=O
InChi Code
InChI=1S/C201H319N49O65S2.C2H4O2/c1-101(2)82-127(229-169(282)119(55-45-76-202)219-151(268)92-214-187(300)159(109(14)254)241-166(279)107(12)217-180(293)138-99-317-100-316-98-137(223-149(266)71-66-118(203)196(309)310)181(294)231-131(88-144(205)261)176(289)243-160(110(15)255)189(302)218-108(13)167(280)242-161(111(16)256)192(305)237-138)173(286)216-106(11)165(278)224-123(70-75-156(275)276)182(295)246-201(19,91-116-52-39-36-40-53-116)199(315)238-128(83-102(3)4)174(287)240-158(105(9)10)188(301)226-121(56-46-78-212-200(209)210)171(284)235-136(97-253)179(292)236-135(96-252)178(291)234-133(89-145(206)262)193(306)247(20)142(90-146(207)263)185(298)232-129(86-114-50-37-35-38-51-114)168(281)215-94-153(270)248-79-47-57-139(248)183(296)225-120(54-43-44-77-211-147(264)72-67-124(197(311)312)221-150(267)73-68-125(198(313)314)220-148(265)60-41-33-31-29-27-25-23-21-22-24-26-28-30-32-34-42-61-154(271)272)170(283)233-132(84-103(5)6)194(307)250-81-49-59-141(250)195(308)249-80-48-58-140(249)184(297)245-163(113(18)258)190(303)227-122(69-74-155(273)274)172(285)239-157(104(7)8)186(299)213-93-152(269)222-134(95-251)177(290)230-130(87-143(204)260)175(288)244-162(112(17)257)191(304)228-126(164(208)277)85-115-62-64-117(259)65-63-115;1-2(3)4/h35-40,50-53,62-65,101-113,118-142,157-163,251-259H,21-34,41-49,54-61,66-100,202-203H2,1-20H3,(H2,204,260)(H2,205,261)(H2,206,262)(H2,207,263)(H2,208,277)(H,211,264)(H,213,299)(H,214,300)(H,215,281)(H,216,286)(H,217,293)(H,218,302)(H,219,268)(H,220,265)(H,221,267)(H,222,269)(H,223,266)(H,224,278)(H,225,296)(H,226,301)(H,227,303)(H,228,304)(H,229,282)(H,230,290)(H,231,294)(H,232,298)(H,233,283)(H,234,291)(H,235,284)(H,236,292)(H,237,305)(H,238,315)(H,239,285)(H,240,287)(H,241,279)(H,242,280)(H,243,289)(H,244,288)(H,245,297)(H,246,295)(H,271,272)(H,273,274)(H,275,276)(H,309,310)(H,311,312)(H,313,314)(H4,209,210,212);1H3,(H,3,4)/t106-,107-,108-,109+,110+,111+,112+,113+,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,
InChi Key
YGUWIKBQJAPQDK-RACGBTHRSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $230

    Add

    5 mg

    $575

    Add

    10 mg

    $920

    Add

    25 mg

    $1,725

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Eloralintide is an agonist of the amylin 1 (AMY1) receptor.1 It selectively activates the AMY1 receptor over the calcitonin and AMY3 receptors in cAMP activation assays using UM-UC-3 cells expressing the human receptors (EC50s = 23.9, 291, and 253.8 pM, respectively). Eloralintide reduces food intake and induces a loss of up to 12.3% of body weight, primarily through reductions in fat mass, in diet-induced obese (DIO) rats at 3-100 nmol/kg per animal.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Briere, D.A., Qu, H., Lansu, K., et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol. Metab. 102, 102271 (2025).